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Small cell carcinoma of the gallbladder is a rare disease process with approximately 40 cases reported in the literature. It is most
often found in elderly female population and is associated with cholelithiasis and cigarette smoking. A multidisciplinary approach
to treatment with wide surgical resection and adjuvant chemotherapy is the current standard of care. Notwithstanding prompt
medical intervention, it is a disease with a poor prognosis. The pathology is characterized by early metastases and extensive local
invasion. Herein, we report two cases of small cell carcinoma addressed at our institution. In both cases, a radical resection was
performed with subsequent referral to oncology for additional therapy.
1.Introduction
Approximately 7000 new cases of gallbladder carcinoma are
diagnosed every year [1]. It is a disease process characterized
by its insidious onset and advanced stage at presentation,
often rendering resection impossible and resulting in an
overall median survival of six months [2]. First described
in 1981, gallbladder neuroendocrine carcinomas make up a
small fraction of this already uncommon tumor [3]. These
tumors may be secretory with symptoms arising due to the
production of biologically active peptides [4]. Conversely,
they can be nonsecretory with symptoms presenting due to
mass eﬀect and disease progression. The overall ﬁve-year
survival rate for gallbladder cancer is approximately ﬁve
percent[5].Thesurvivalrateforneuroendocrinecarcinomas
is even less due to its high malignant potential and late
stage at presentation [6, 7]. Herein, we report two cases
of neuroendocrine carcinoma diagnosed and resected in
otherwise healthy individuals.
2.Case1
A-47-year-old male presented to an outside hospital with
a 48-hour history of epigastric and right-upper quadrant
abdominal pain. A review of systems was grossly negative
at presentation. An RUQ ultrasound and MRI performed
revealed a heterogeneous mass arising from the gallbladder
measuring 7.5×5.4cm and extending into segment 4B of the
liver (Figure 1). Liver function tests, CEA, and CA19-9 were
remarkable only for a mildly elevated GGT of 84.
The patient was taken to the operating room for a
laparoscopic exploration and surgical resection. Exploratory
laparoscopy yielded no evidence of metastatic disease. The
gallbladder was excised en bloc with a subsegmental liver
resection of segment 4B. Pathology was consistent with
ap o o r l yd i ﬀerentiated neuroendocrine carcinoma with
extensive lymphovascular invasion (Figures 2 and 3). The
Azzopardi phenomenon, a feature of small cell carcinoma,
was present (Figure 4). An immunohistochemical analysis
conﬁrmed the diagnosis (Table 1).
The patient recovered from the intervention without
complication. He has since received a six-week course of
54Gy of radiotherapy with a concurrent chemotherapy reg-
imen of cisplatin and etoposide. Currently, this individual is
eight months out from his initial operation andis doing well.
3.Case2
A 41-year-old female presented to an outside institution
with symptoms consistent with biliary dyskinesia for which
an uncomplicated laparoscopic cholecystectomy was per-
formed. The pathology returned with an incidental ﬁnding2 Case Reports in Medicine
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Figure 1: Neuroendocrine tumor of the gallbladder in an otherwise asymptomatic 47-year-old male. (a) Coronal T1-weighted image shows
a7 .5 × 5.4cm irregular mass arising from the gallbladder bed. (b) Coronal T1-weight image again illustrating the large heterogeneous mass
in the gallbladder fossa.
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Figure 2: Grossly, the intramural tumor mass occupies over 95% of
the gallbladder wall and protrudes into the lumen. The tumor mass
has a solid tan-red colored ﬂeshy cut surface.
Figure 3: The tumor diﬀusely inﬁltrates into the gallbladder wall
and involves the mucosa. (HE) ×20.
of a well-diﬀerentiated neuroendocrine carcinoma of the
cystic duct. The mass was 0.4 centimeters in largest diameter
with the proximal margin of the cystic duct positive for
malignancy. An MRI and abdominal CT scan performed at
Figure 4: In the higher magniﬁcation, nuclear moldings with many
abnormalmitosis,apoptoticcells,andnecrosisareseen.(HE) ×400.
that time were negative for any evidence of residual tumor
or metastatic disease. She was subsequently referred to this
institution for additional surgical treatment.
Following the completion of a negative metastatic work
up with laboratory analyses and an Octreoscan, the patient
was taken to the operative suite for re-exploration. The
cystic duct remnant was resected at its origin, and a wide
portal lymphadenectomy was completed. When the frozen
pathology returned with no evidence of residual tumor, the
operation was concluded.
The patient tolerated the procedure well. Pathology
ﬁndings were negative for any additional tumor. She has
since been treated with adjuvant chemotherapy by medical
oncology. A repeat octreotide scan two months postopera-
tively documented no recurrent or metastatic disease.
4. Discussion
Gallbladder carcinoma is the ﬁfth most common gastroin-
testinal malignancy with 7000 new cases diagnosed in the
United States each year [1]. The preponderance of these
tumors is adenocarcinoma [4, 5]. It is a disease with few
well-described risk factors. These include choledochal cysts,Case Reports in Medicine 3
Figure 5: The Azzopardi phenomenon: basophilic dark blue
DNA/nuclear chromatin liberated from dead cells coats vessel walls.
(HE) ×400.
Figure 6: The tumor cells are strongly diﬀuse positive for chro-
mogranin A (Immunohistochemical stain, original magniﬁcation,
×400). (IHC).
Table 1
Immunohistochemical stains Tumor response to
stain
Synaptophysin Positive
Chromogranin Positive
CD56 Positive
CD57 Positive
Cytokeratin AE1/AE3 Negative
TTF1 Negative
CD45 Negative
Ki-67 Positive (>90%
Tumor cells)
gallstones larger than three centimeters, and chronic states of
inﬂammation [2]. Due to the lack of systemic symptoms, it
often presents at an advanced stage with only ten percent of
cases conﬁned to the gallbladder wall at the time of diagnosis
[8]. It is because of this insidious presentation that the
overall survival rate is less than 5%. To date, there has been
minimal research conducted as to the medical treatment
of this disease with most trials being underpowered or
overinclusive with multiple tumor types enrolled in the trial.
Adjuvant chemotherapy is often used but is without a well-
deﬁned protocol. Therapeutic interventions are currently
limited to complete surgical resection with negative margins.
Unfortunately, resection is feasible in no more than 25%
of patients due to the advanced nature of their disease at
presentation.
Neuroendocrine carcinomas represent an even smaller
percentage of the general surgeon’s practice. Carcinoid
tumors comprise the majority of this pathology, with as
many as 68% originating from the gastrointestinal tract
[9]. The varied presentation of this tumor is based on its
embryologic origin and may include mass eﬀect, bleeding,
or the classic carcinoid syndrome. The gallbladder small cell
neuroendocrine tumor is an exceedingly rare malignancy
comprising 0.2% of all gastrointestinal carcinoids [10]. It is
typicallyanonfunctional tumorwithoutovert clinical symp-
toms secondary to secretion of biologically active peptides
[9]. Furthermore, it is often discovered late in the disease
process when adjacent organ systems have been violated
or the biliary system becomes obstructed. Consequently,
the prognosis is poor with survival rates worse than other
gallbladder malignancies.
There have been limited discussions of this pathology in
the literature to date, principally in the form of case reports
orsmallcaseseries.Itisadiseasethatmostcommonlyaﬀects
an elderly, female population [11]. Similar to adenocarci-
noma,thereisastrongassociationbetweencholelithiasisand
this tumor. Interestingly, there are no neuroectodermal cells
in the gallbladder mucosa [12] .T h i sh a dl e a di n v e s t i g a t o r s
to postulate that the small cell carcinoma arises from
metaplastic epithelium of the gallbladder wall [13]. This
hypothesis is supported by the presence of metaplasia in the
gallbladder with chronic cholecystitis [14]. Distant disease at
presentation is present as much as 75% of the time and is
mostoftenlocatedintheliverandadjacentlymphnodes[5].
Due to the scarcity of this neoplasm, diagnostic criteria
in the form of radiologic ﬁndings and preoperative tumor
markers are poorly described. Furthermore, given the insid-
ious nature of the mass, diagnosis can be diﬃcult without
a histologic analysis. For instance, in the ﬁrst patient, the
MRI was notable for a large, inﬁltrating mass. There were no
notable abnormalities in the laboratory work up including
CEA and CA19-9. In the second subject, it was not until after
the therapeutic cholecystectomy for acute cholecystitis that
the mass was incidentally discovered. Even with imaging, it is
often not until the histopathologic analysis is complete that
the diagnosis of a neuroendocrine tumor is reached.
Therapeutic options for this pathology are often limited
due to the advanced nature of the disease at diagnosis.
Surgicalexcisionremainsthebestoptionforacure.However,
the necessity of a radical resection and the extent of
surrounding tissue removed are debated in the literature
[15]. In those patients not amenable to a curative operation-
diﬀerent chemotherapy regimens are described [4, 6, 16,
17]. Patients treated with surgical excision and adjuvant
chemotherapy have an increased median survival from 4.5
to 13 months [11]. With that said, no randomized, blinded4 Case Reports in Medicine
trials have been performed to validate one regimen as the
gold standard treatment.
5. Conclusion
Gallbladder neuroendocrine carcinomas remain an excep-
tionally rare malignancy with a strikingly poor prognosis.
Early diagnosis with prompt surgical intervention provides
the patient with the best long-term outcome. Adjuvant
chemotherapy provides a deﬁnable survival advantage to
the patient but is without a well-deﬁned standard of care
protocol.
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